{"entity":{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","aka":["BWXT Medical Ltd."],"tldr":"A Canadian company, owned by the US nuclear firm BWXT, that is building a made-in-Canada supply of the technetium generators hospitals use for the vast majority of nuclear medicine scans, plus other isotopes and radiotherapy hardware.","summary":"BWXT Medical Ltd. is the nuclear medicine subsidiary of BWX Technologies, Inc. (NYSE: BWXT), operating manufacturing and processing facilities in Ottawa and Vancouver, Canada. Its central programme is a proprietary route to molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), the radionuclide used in roughly 80% of nuclear medicine procedures worldwide. Rather than irradiating enriched-uranium targets in a research reactor, BWXT's approach irradiates natural molybdenum targets in an operating commercial power reactor: since 2018/2019 it has worked with Ontario Power Generation and its subsidiary Laurentis Energy Partners to install a Target Delivery System (TDS) at OPG's Darlington Nuclear Generating Station, making Darlington the first commercial power reactor in the world to produce Mo-99. The Mo-99 is processed at BWXT Medical's Ottawa facility into proprietary Tc-99m generators intended as drop-in replacements for existing hospital and radiopharmacy generators, pending FDA and Health Canada approval; a February 2023 milestone confirmed installation and initial commissioning of the isotope system at Darlington.\n\nBWXT Medical's isotope portfolio extends beyond Mo-99/Tc-99m: industry directory material describes it as also handling actinium-225, indium-111, iodine-123, strontium-82 and germanium-68, and as pursuing cobalt-60 production at Darlington (alongside existing extraction at OPG's Pickering station). The company is also the exclusive contract manufacturer, outside China, of TheraSphere (yttrium-90 glass microspheres for radioembolisation) in partnership with Boston Scientific, and has worked with Laurentis on scalable production infrastructure at Darlington intended to support lutetium-177 as well as Mo-99.\n\nAs a large, reactor-adjacent contract manufacturer, BWXT Medical sits in the therapeutic and diagnostic isotope supply chain alongside other Mo-99/Tc-99m producers (Curium, NTP Radioisotopes, ANSTO) and complements Boston Scientific's radioembolisation device business through its TheraSphere manufacturing role.","status":"active","asOf":"2026-09-22","links":[{"label":"BWXT Medical: BWXT Medical and Laurentis complete key Tc-99m generator program milestone (2023)","url":"https://www.bwxtmedical.com/bwxt-medical-and-laurentis-complete-key-tc-99m-generator-program-milestone/"},{"label":"BWXT Medical: Tc-99m generators product sheet (PDF)","url":"https://bwxtmedical.com/wp-content/uploads/2024/05/tc-99m-product-sheet.pdf"},{"label":"BWXT Medical: BWXT Names Nuclear Medicine Business as BWXT Medical (2021)","url":"https://www.bwxtmedical.com/bwxt-names-nuclear-medicine-business-as-bwxt-medical/"},{"label":"BWXT/OPG: OPG and BWXT make significant progress in production of Mo-99 at Darlington (2020)","url":"https://www.bwxt.com/opg-and-bwxt-make-significant-progress-in-production-of-life-saving-medical-isotope-at-darlington-nuclear-generating-station-2/"},{"label":"CNIC: Canadian Isotope Ecosystem Directory 2025 (BWXT Medical entry, PDF)","url":"https://s45591.pcdn.co/wp-content/uploads/2025/12/2025-CNIC-Medical-Isotope-Ecosystem-Directory-DEC2025-AX.pdf"}],"tags":["molybdenum-99","technetium-99m","generator","radioembolisation"],"related":["research-reactor-isotope-production","radioembolisation-tare","boston-scientific","therapy-isotope-supply-chain","tc-99m","i-123","in-111","mo-99","ge-68","lu-177","ac-225","y-90"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ottawa, Ontario, Canada","country":"CA","companyType":"radiopharma","website":"https://www.bwxtmedical.com","stage":"acquired","investors":[],"funding":[]},"route":"/companies/bwxt-medical/","neighbours":{"technology":[{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"company":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/"}],"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/"},{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/"},{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/"},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/"},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}]}}